NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions

Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Breast CancerAdvanced Lung CarcinomaNSCLCNSCLC, RecurrentNSCLC Stage IVRelapsed CancerRelapse/RecurrenceRecurrent Breast CancerRecurrent NSCLCPlatinum-resistant Ovarian CancerOvarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerEndometrioid TumorHigh Grade Serous CarcinomaOvarian Epithelial Cancer

Interventions

BIOLOGICAL

LYL797

LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy

Trial Locations (18)

10065

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, The Bronx

19107

Sidney Kimmel Cancer Center, Jefferson University Hospital, Philadelphia

20007

Georgetown University, Washington D.C.

32224

Mayo Clinic, Jacksonville

33136

University of Miami, Miami

37203

Sarah Cannon Research Institute and Tennessee Oncology, Nashville

48201

Karmanos Cancer Institute, Detroit

53226

Froedtert Hospital, Medical College of Wisconsin, Milwaukee

55902

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

73104

University of Oklahoma, Oklahoma City

77030

MD Anderson Cancer Center, Houston

85259

Mayo Clinic, Scottsdale

90404

University of California, Los Angeles, Santa Monica

97239

Oregon Health and Science University Hospital, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

06510

Yale New Haven Hospital, New Haven